Cargando…

TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas

OBJECTIVE: This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chen, Han, Sheng, Meng, Lingxuan, Li, Zhonghua, Zhang, Xue, Wu, Anhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061075/ https://www.ncbi.nlm.nih.gov/pubmed/24937153 http://dx.doi.org/10.1371/journal.pone.0100297

Ejemplares similares

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Significance of TERT and ATRX mutations in glioma
por: Liu, Jiayu, et al.
Publicado: (2019)

PMA and Ionomycin Induce Glioblastoma Cell Death: Activation-Induced Cell-Death-Like Phenomena Occur in Glioma Cells
por: Han, Sheng, et al.
Publicado: (2013)

TERT rs2853676 polymorphisms correlate with glioma prognosis in Chinese population
por: He, Xue, et al.
Publicado: (2016)

Secretory Pathway Kinase FAM20C, a Marker for Glioma Invasion and Malignancy, Predicts Poor Prognosis of Glioma
por: Du, Shaonan, et al.
Publicado: (2020)

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas
por: Gao, Ke, et al.
Publicado: (2015)

Plasma IGFBP-2 Levels after Postoperative Combined Radiotherapy and Chemotherapy Predict Prognosis in Elderly Glioblastoma Patients
por: Han, Sheng, et al.
Publicado: (2014)

The Effect of Temozolomide/Poly(lactide-co-glycolide) (PLGA)/Nano-Hydroxyapatite Microspheres on Glioma U87 Cells Behavior
por: Zhang, Dongyong, et al.
Publicado: (2012)

Relationship between IDH1/2 and TERT promoter mutation and the prognosis of human glioma patients
por: Liu, Xipeng, et al.
Publicado: (2023)

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma
por: Gao, Mengqi, et al.
Publicado: (2021)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma
por: Blateau, Pauline, et al.
Publicado: (2020)

pTERT C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma
por: Blanco-García, Leyla, et al.
Publicado: (2023)

Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo
por: Yu, Zhiyun, et al.
Publicado: (2015)

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
por: Kikuchi, Zensho, et al.
Publicado: (2020)

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
por: Lee, Yujin, et al.
Publicado: (2017)

Human TERT promoter mutations as a prognostic biomarker in glioma
por: Powter, Branka, et al.
Publicado: (2021)

Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
por: Filippi-Chiela, Eduardo C, et al.
Publicado: (2013)

Bromodomain PHD-finger transcription factor promotes glioma progression and indicates poor prognosis
por: Pan, Yanling, et al.
Publicado: (2019)

Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers
por: Guo, Wei, et al.
Publicado: (2014)

Differential Characterization of Temozolomide-Resistant Human Glioma Cells
por: Lai, Sheng-Wei, et al.
Publicado: (2018)

TERT Promoter Mutations Increase Sense and Antisense Transcription from the TERT Promoter
por: Hafezi, François, et al.
Publicado: (2021)

Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma
por: Bai, Ming, et al.
Publicado: (2022)

Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells
por: Liu, Zhendong, et al.
Publicado: (2021)

Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients
por: Wang, Jialin, et al.
Publicado: (2021)

TZAP Mutation Leads to Poor Prognosis of Patients with Breast Cancer †
por: Heo, Yu-Ran, et al.
Publicado: (2019)

TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma
por: Paulsson, Johan O., et al.
Publicado: (2018)

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
por: Heidenreich, Barbara, et al.
Publicado: (2015)

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
por: Labussière, M, et al.
Publicado: (2014)

Comprehensive analysis of HHV‐6 and HHV‐7‐related gene signature in prognosis and response to temozolomide of glioma
por: Chen, Luoyi, et al.
Publicado: (2022)

The increasing expression of GPX7 related to the malignant clinical features leading to poor prognosis of glioma patients
por: Yao, Jiawei, et al.
Publicado: (2021)

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy
por: Hu, Li, et al.
Publicado: (2021)

Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide
por: Lorenz, Nadja I., et al.
Publicado: (2021)

β-elemene combined with temozolomide in treatment of brain glioma
por: Zhang, Xiaomin, et al.
Publicado: (2021)

Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide
por: Yang, Zhang-Jian, et al.
Publicado: (2021)

Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide
por: Maurer, Gabriele D., et al.
Publicado: (2019)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oelvnmhtb9lscmr98nn5sp8qdr